Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Donʼt Forget the Role of Cyclosporin

2012 ◽  
Vol 18 (8) ◽  
pp. E1594-E1595 ◽  
Author(s):  
Emanuele Sinagra ◽  
Ambrogio Orlando ◽  
Sara Renna ◽  
Marcello Maida ◽  
Mario Cottone
2012 ◽  
Vol 302 (10) ◽  
pp. G1163-G1170 ◽  
Author(s):  
Kazuhiko Uchiyama ◽  
Yuji Naito ◽  
Tomohisa Takagi ◽  
Katsura Mizushima ◽  
Yasuko Hirai ◽  
...  

Serpin B1 is a monocyte neutrophil elastase (NE) inhibitor and is one of the most efficient inhibitors of NE. In the present study, we investigated the role of serpin B1 in the pathogenesis of ulcerative colitis by using clinical samples and an experimental model. The colonic expression of serpin B1 was determined by real-time polymerase chain reaction (PCR), Western blot analysis, and immunohistological studies in both normal and inflamed mucosa from patients with ulcerative colitis. Serpin B1 mRNA expression was determined by real-time PCR in the mouse dextran sodium sulfate (DSS)-induced colitis model. Young adult mouse colonic epithelial (YAMC) cells were used to determine the role of serpin B1. Serpin B1 gene transfected YAMC cells were treated with H2O2 to measure cell viability. The expression of NE was determined in YAMC cells treated with H2O2. NE-silenced YAMC cells were also treated with H2O2 and then measured for viability. Upregulated expression of serpin B1 in colonic mucosa was confirmed from patients with active ulcerative colitis. Immunohistochemical studies showed that serpin B1 expression was localized not only in inflammatory infiltration cells but also in epithelial cells. Serpin B1 mRNA expression was also increased in colonic mucosa of mouse DSS-induced colitis. Serpin B1-transfected YAMC cells were resistant against the treatment of H2O2. H2O2 treatment significantly induced NE in YAMC cells, and NE-silenced YAMC cells were also resistant against the treatment of H2O2. These results suggest that serpin B1 may be a novel marker of active ulcerative colitis and may play an important role in the pathogenesis of inflammatory bowel disease.


2005 ◽  
Vol 100 ◽  
pp. S299-S300
Author(s):  
Michael F. Picco ◽  
Jeremy C. Davis ◽  
John R. Cangemi ◽  
Donna Shelton

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S178-S178
Author(s):  
A Giordano ◽  
M Ribolsi ◽  
P Balestrieri ◽  
S Emerenziani ◽  
M Cicala

2013 ◽  
Vol 7 ◽  
pp. S61
Author(s):  
E.S. Kim ◽  
Y.T. Jeen ◽  
B. Keum ◽  
B.J. Lee ◽  
J.S. Koo ◽  
...  

2011 ◽  
Vol 50 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Atsushi Yoshida ◽  
Kenji Kobayashi ◽  
Fumiaki Ueno ◽  
Eiki Yoshimatsu ◽  
Keiji Matsui ◽  
...  

2013 ◽  
Vol 144 (5) ◽  
pp. S-618
Author(s):  
Takumi Fukuchi ◽  
Hiroshi Nakase ◽  
Minoru Matsuura ◽  
Takuya Yoshino ◽  
Takahiko Toyonaga ◽  
...  

2020 ◽  
Vol 8 ◽  
pp. 2050313X2096411
Author(s):  
Maria Mikail ◽  
Aze Wilson

Pyoderma gangrenosum is an uncommon neutrophilic dermatosis that is highly associated with pathergy in the setting of trauma or surgery, systemic disease, or may be idiopathic. Herein, we present the case of a 68-year-old female with ulcerative colitis who underwent a subtotal colectomy with an end-ileostomy and presented post-operatively with large, multifocal pyoderma gangrenosum at two abdominal sites. She was managed with intralesional triamcinolone injections and high-dose systemic steroids and was transitioned to IV infliximab. Our case report illustrates the role of infliximab in the treatment of complicated multifocal pyoderma gangrenosum and contemplates the impact of systemic infliximab exposure.


2014 ◽  
Vol 8 (3) ◽  
pp. 215-222 ◽  
Author(s):  
Paolo Gionchetti ◽  
Chiara Praticò ◽  
Fernando Rizzello ◽  
Andrea Calafiore ◽  
Nunzia Capozzi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document